SYRE Reports $0 Revenue, $0 EPS, +9.2 Pt RHI Reduction, 40% Clinical Remission, 51% Endoscopic Improvement, Phase 2 SKYLINE Trial Success, Conference Call Today
Spyre Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $70.54
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS